Toby Maher, Royal Brompton Hospital, London, met with us at ERS 2019 in Madrid to discuss the results of a Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD).

Questions
1. What is the definition of unclassifiable interstitial lung disease (uILD) and what proportion of ILD patients are considered unclassifiable? (0:05)
2. What is the current standard of care for patients with progressive fibrosing uILD? (0:44)
3. Could you tell us a little about the design and findings of the recent study investigating pirfenidone in patients with progressive fibrosing uILD? (1:11)
4. Which patients are most likely to respond to this treatment approach? (1:55)
5. What further studies are planned? (2:33)

Speaker disclosures: Toby Maher has received consultancy fees, travel expenses and honoraria from Roche and Boehringer Ingelheim.

touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Filmed at the European Respiratory Society (ERS) International Congress 2019, Madrid, Spain.

свернуть